MG1111 (BARYCELA) versus VARIVAX for preventing chickenpox in children 1 to 12 years

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3 interventional trial compares the safety and immunogenicity of the MG1111 (BARYCELA) vaccine with the licensed VARIVAX vaccine in healthy children aged 12 months to 12 years. Participants will receive two vaccine doses and be monitored for 42 days after the second dose for safety and immune response measurements. The study includes long-term surveillance for up to 10 years to record any varicella infections. The trial is sponsored by GC Biopharma Corp and conducted at Srinagarind Hospital in Khon Kaen, Thailand.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participant must be 12 months to 12 years of age, inclusive, at the time of signing the informed consent or assent.
* Participant is overtly healthy as determined by the investigator

Exclusion Criteria:

* Participants with a history of exposure to varicella through contact with a varicella patient at home, school, or childcare facility within 4 weeks before Screening
* Participants with a history of varicella infection and varicella vaccine, either licensed or investigational, and either standalone or any combination, such as MMRV
* Participants with acute moderate or severe infection with or without fever at the time of dosing
* Participants who have had any suspected allergy symptoms, such as systemic rash, during the 72 hours before each administration of investigational product

Where it's running

• Srinagarind Hospital
  Khon Kaen, Changwat Khon Kaen, Thailand Recruiting

Study contacts

• Study coordinator: Minji Ko
• Email: mg1111d@gccorp.com
• Phone: +82-31-260-9143

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Second dose of chickenpox (varicella) vaccine for healthy children

  This project will give a Sinovac second dose of the chickenpox vaccine to children aged 15 months–12 years who had a first dose at 12 months to see if switching brands is safe and produces good immune responses.

  Recruiting at 2 sites Phase 3 Sinovac (Dalian) Vaccine Technology Co., Ltd. · Akdeniz and 4 other locations · NCT07475000

• Varicella vaccine with lower potencies in healthy children aged 12 months to 12 years

  This test compares an investigational varicella vaccine called NBP608 with licensed vaccines in children aged 12 months to 12 years to see if it is safe and can provoke an immune response.

  Recruiting at 8 sites Phase 3 SK Bioscience Co., Ltd. · San Pedro Sula, Cortés Department and 13 other locations · NCT07415252

• Measles, Mumps, Rubella and Varicella vaccine booster in healthy children aged 15 months to 6 years

  This study tests whether the investigational MMRVNS vaccine given as a second dose is safe and can provoke an immune response in healthy children who previously received a first MMRV-containing vaccine dose.

  Recruiting at 17 sites Phase 3 GlaxoSmithKline · Birmingham, Alabama and 16 other locations · NCT07406360

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.